Preoperative PET/CT in early-stage breast cancer
Open Access
- 21 February 2012
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 23 (9) , 2277-2282
Abstract
The aim of this study was to assess the diagnostic and therapeutic impact of preoperative positron emission tomography and computed tomography (PET/CT) in the initial staging of patients with early-stage breast cancer. A total of 103 consecutive patients with newly diagnosed operable breast cancer with tumors ≥2 cm were independently examined preoperatively with conventional assessment (mammography, breast/axillary ultrasound, chest X-ray and blood samples) and PET/CT with no prior knowledge of the other. PET/CT identified a primary tumor in all but three patients (97%). PET/CT solely detected distant metastases (ovary, bones and lung) in 6 patients and new primary cancers (ovary, lung) in another two patients, as well as 12 cases of extra-axillary lymph node involvement. In 15 patients (15%), extra-axillary malignancy was detected by PET/CT only, leading to an upgrade of initial staging in 14% (14/103) and ultimately a modification of planned treatment in 8% (8/103) of patients. PET/CT is a valuable tool to provide information on extra-axillary lymph node involvement, distant metastases and other occult primary cancers. Preoperative 18F-fluorodeoxyglucose–PET/CT has a substantial impact on initial staging and on clinical management in patients with early-stage breast cancer with tumors ≥2 cm.Keywords
This publication has 21 references indexed in Scilit:
- Integrated contrast-enhanced diagnostic whole-body PET/CT as a first-line restaging modality in patients with suspected metastatic recurrence of breast cancerEuropean Journal of Radiology, 2010
- Preoperative Staging of Large Primary Breast Cancer With [18F]Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Compared With Conventional Imaging ProceduresJournal of Clinical Oncology, 2008
- PET/CT supports breast cancer diagnosis and treatmentBreast Cancer, 2008
- FDG PET, PET/CT, and Breast Cancer ImagingRadioGraphics, 2007
- Therapeutic impact of 2-[fluorine-18]fluoro-2-deoxy-D-glucose positron emission tomography in the pre- and postoperative staging of patients with clinically intermediate or high-risk breast cancerAnnals of Oncology, 2007
- Initial experience with FDG-PET/CT in the evaluation of breast cancerEuropean Journal of Nuclear Medicine and Molecular Imaging, 2005
- Value of fluorodeoxyglucose positron emission tomography in women with breast cancerBritish Journal of Surgery, 2005
- Comparison of fluorodeoxyglucose positron emission tomography and ‘conventional diagnostic procedures’ for the detection of distant metastases in breast cancer patientsNuclear Medicine Communications, 2002
- Fluorine-18 2-deoxy-2-fluoro-D-glucose PET in the preoperative staging of breast cancer: comparison with the standard staging proceduresEuropean Journal of Nuclear Medicine and Molecular Imaging, 2001
- Assessment of Primary and Metastatic Ovarian Cancer by Positron Emission Tomography (PET) Using 2-[18F]Deoxyglucose (2-[18F]FDG)Gynecologic Oncology, 1993